{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-003877","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2026-06-02T20:01:17+00:00","discovered_at":"2026-06-02T20:02:00.608600+00:00","generated_at":"2026-06-02T20:02:12.952222+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Stockholders approve 400,000-share increase in 2021 Incentive Plan and amendment to ESPP","bullets":["Stockholders elected John Duke and Katherine A. Eade as Class II directors for three-year terms.","Ratified Grant Thornton LLP as independent auditor for FY2026; 2,781,705 votes for, 13,975 against.","Non-binding advisory vote approved named executive officer compensation: 1,768,695 for, 57,111 against.","Amended ESPP increases authorized shares from 310,000 to 1,900,000 (approx. 1.59M share increase).","Amended 2021 Incentive Plan increases authorized shares by 400,000 (from 646,520 available as of Dec 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003877","json":"https://secwatch.observer/filing/0001171843-26-003877.json","markdown":"https://secwatch.observer/filing/0001171843-26-003877.md","text":"https://secwatch.observer/filing/0001171843-26-003877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/f8k_060226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T20:02:12.952222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18191a756ad9442e92e8b1d10d9d8a0a0023c12f","claim":"HARVARD BIOSCIENCE INC shareholders approved Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","confidence":0.9},{"claim_id":"646754887239498f802fb15235e998235046c7e6","claim":"HARVARD BIOSCIENCE INC shareholders approved Election of two Class II Directors at the 2026-06-02 meeting.","evidence_excerpt":"On June 2, 2026, the Company held its Annual Meeting, at which the Company’s stockholders voted on five proposals that are described in detail in the Definitive Proxy Statement. The voting results for each of the proposals are reported below. Proposal 1 - Election of Directors The Company’s stockholders elected two Class II Directors for three-year terms, such terms to continue until the annual meeting of stockholders in 2029 and until such Directors’ successors are duly elected and qualified or until his or her earlier resignation or removal: Name Votes For Votes Withheld Broker Non-Votes John Duke 1,800,288 28,703 970,538 Katherine A. Eade 1,680,982 148,009 970,538","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","confidence":0.9},{"claim_id":"883350bf0054641d528b952b896a550b74e3741c","claim":"HARVARD BIOSCIENCE INC shareholders approved Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 3 –Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved the compensation of the Company’s named executive officers by a non-binding advisory vote, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,768,695 57,111 3,185 970,538","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","confidence":0.9},{"claim_id":"93d1eab07ef3d0ad79dd5d7d3bebeaeff881e887","claim":"HARVARD BIOSCIENCE INC shareholders approved Approval of the Amended and Restated 2021 Incentive Plan at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 5 – Approval of the Amended and Restated 2021 Incentive Plan The Company’s stockholders approved the Amended and Restated 2021 Incentive Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,131,261 680,030 17,700 970,538","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","confidence":0.9},{"claim_id":"ffc5262c3a4c3101da0e9b7e475d69fdbfe2b8fa","claim":"HARVARD BIOSCIENCE INC shareholders approved Ratification of the Appointment of Grant Thornton LLP at the 2026-06-02 meeting.","evidence_excerpt":"Proposal 2 –Ratification of the Appointment of Grant Thornton LLP The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as follows: Votes For Votes Against Votes Abstained 2,781,705 13,975 3,849","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001171843-26-003793","ticker":"EDSA","company_name":"Edesa Biotech, Inc.","filed_at":"2026-05-29T20:15:18+00:00","headline":"Edesa Biotech shareholders approve equity plan amendment adding 750K shares","event_type":"other","sec_items":["5.02","5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.02, 5.07, 9.01","same event type: other","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003793","json":"https://secwatch.observer/filing/0001171843-26-003793.json","markdown":"https://secwatch.observer/filing/0001171843-26-003793.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326003793/0001171843-26-003793-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326003793/f8k_052226.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","comparable_excerpt":"Proposal No. 3 - Approval of Amendment to the 2019 Equity Incentive Compensation Plan The shareholders approved an amendment to the Company’s 2019 Plan to (i) increase the number of shares available for issuance thereunder plan by 750,000 shares and (ii) eliminate the annual per participant option grant limit. For Against Abstain Broker Non-Votes 2,613,551 130,589 10,680 2,147,101","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326003793/0001171843-26-003793-index.htm"}},{"accession":"0001193125-26-253825","ticker":"ACIW","company_name":"ACI WORLDWIDE, INC.","filed_at":"2026-06-02T21:08:06+00:00","headline":"ACI Worldwide annual meeting approves all proposals including director elections","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.0,"calibrated_materiality_score":0.0,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253825","json":"https://secwatch.observer/filing/0001193125-26-253825.json","markdown":"https://secwatch.observer/filing/0001193125-26-253825.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/935036/000119312526253825/0001193125-26-253825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/935036/000119312526253825/d92029d8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","comparable_excerpt":"The stockholders approved, on an advisory basis, the named executive compensation as described in the 2026 Proxy Statement.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/935036/000119312526253825/0001193125-26-253825-index.htm"}},{"accession":"0001193125-26-253604","ticker":"KYTX","company_name":"Kyverna Therapeutics, Inc.","filed_at":"2026-06-02T20:30:16+00:00","headline":"Kyverna Therapeutics shareholders elect Ian Clark and Christi Shaw as Class II directors, ratify BDO USA auditor","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.15,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253604","json":"https://secwatch.observer/filing/0001193125-26-253604.json","markdown":"https://secwatch.observer/filing/0001193125-26-253604.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526253604/0001193125-26-253604-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526253604/kytx-20260527.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","comparable_excerpt":"Director Nominee Votes For Votes Withheld Broker Non-Votes Ian Clark 31,505,902 3,255,231 9,225,874 Christi Shaw 34,528,865 232,268 9,225,874","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1994702/000119312526253604/0001193125-26-253604-index.htm"}},{"accession":"0001104659-26-069461","ticker":"PARK","company_name":"Park Dental Partners, Inc.","filed_at":"2026-06-02T20:05:32+00:00","headline":"Park Dental Partners announces shareholder voting results at 2026 annual meeting","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.1,"calibrated_materiality_score":0.1,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069461","json":"https://secwatch.observer/filing/0001104659-26-069461.json","markdown":"https://secwatch.observer/filing/0001104659-26-069461.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2069604/000110465926069461/0001104659-26-069461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2069604/000110465926069461/tm2616585d1_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","comparable_excerpt":"The Company’s shareholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2069604/000110465926069461/0001104659-26-069461-index.htm"}},{"accession":"0000950103-26-008321","ticker":"ADCT","company_name":"ADC Therapeutics SA","filed_at":"2026-06-02T20:01:37+00:00","headline":"ADC Therapeutics shareholders approve capital range increase, equity plan expansion at 2026 AGM","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-26-008321","json":"https://secwatch.observer/filing/0000950103-26-008321.json","markdown":"https://secwatch.observer/filing/0000950103-26-008321.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/dp247757_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","comparable_excerpt":"Proposal #12 : Approving amendments to articles 4a, 4b and 4c of the articles of association to increase the Company’s capital range (article 4a), conditional share capital for employee participation (article 4b) and conditional share capital for financing, acquisitions and other purposes (article 4c) as well as the introduction of article 4d regarding a conditional share capital based on the capital range The shareholders approved (i) amendments to article 4a paragraph 1 of the articles of association to increase the Company’s capital range from CHF 8,375,974.48 (lower limit) to CHF 12,354,128.80 (upper limit) to CHF 10,378,109.12 (lower limit) to CHF 15,567,163.68 (upper limit) (Proposal #12a), (ii) amendments to article 4b paragraph 1 of the articles of association to increase the Company’s conditional share capital for employee participation from 9,887,629 common shares (CHF 791,010.32) to 16,836,253 common shares (CHF 1,346,900.24) (Proposal #12b)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326008321/0000950103-26-008321-index.htm"}},{"accession":"0001104659-26-069446","ticker":"SGA","company_name":"SAGA COMMUNICATIONS INC","filed_at":"2026-06-02T20:00:26+00:00","headline":"Saga Communications shareholders elect all 7 directors, approve say-on-pay and auditor ratification","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-069446","json":"https://secwatch.observer/filing/0001104659-26-069446.json","markdown":"https://secwatch.observer/filing/0001104659-26-069446.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/886136/000110465926069446/0001104659-26-069446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886136/000110465926069446/sga-20260601x8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","comparable_excerpt":"The seven nominees for election as directors for the ensuing year, and until their successors are elected and qualified, were elected and received the following votes:","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/886136/000110465926069446/0001104659-26-069446-index.htm"}},{"accession":"0001104659-26-068996","ticker":"XBP","company_name":"XBP Global Holdings, Inc.","filed_at":"2026-06-01T21:00:49+00:00","headline":"XBP Global Holdings annual meeting elects directors, approves auditor and say-on-pay","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068996","json":"https://secwatch.observer/filing/0001104659-26-068996.json","markdown":"https://secwatch.observer/filing/0001104659-26-068996.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1839530/000110465926068996/0001104659-26-068996-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1839530/000110465926068996/tm2616124d2_8k.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","comparable_excerpt":"Proposal 4 — To consider and vote upon a proposal to approve, on an advisory (non-binding) basis, the frequency of future say-on-pay votes: Votes For 1 Year Votes For 2 Years Votes For 3 Years Votes Abstained Broker Non-Votes 9,200,507 333 488 332,030 577,920","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1839530/000110465926068996/0001104659-26-068996-index.htm"}},{"accession":"0001628280-26-039483","ticker":"AXON","company_name":"AXON ENTERPRISE, INC.","filed_at":"2026-06-01T20:10:40+00:00","headline":"Axon shareholders elect all 9 director nominees and approve say-on-pay at 2026 annual meeting","event_type":"other","sec_items":["5.07","9.01"],"materiality_score":0.25,"calibrated_materiality_score":0.15,"match_reasons":["same fact type: shareholder_vote","same SEC item: 5.07, 9.01","same event type: other"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039483","json":"https://secwatch.observer/filing/0001628280-26-039483.json","markdown":"https://secwatch.observer/filing/0001628280-26-039483.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069183/000162828026039483/0001628280-26-039483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069183/000162828026039483/axon-20260528.htm"},"side_by_side_evidence":{"fact_type":"shareholder_vote","source_excerpt":"Proposal 4 – Approval of the Amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan The Company’s stockholders approved the amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance thereunder, as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,705,565 90,905 32,521 970,538","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184326003877/0001171843-26-003877-index.htm","comparable_excerpt":"Proposal No. 2 — Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers ( “ Say-on-Pay ” ) The non-binding advisory vote to approve the compensation of the Company’s named executive officers was approved as follows: FOR AGAINST ABSTAIN BROKER NON-VOTES 54,903,698 6,239,017 112,972 11,665,236","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1069183/000162828026039483/0001628280-26-039483-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}